Medicovestor Announces FDA IND Clearance for MC001, Advancing to An International Phase 1 StudyNEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric chemoimmunotherapy ADC for pancreatic cancer, following completion of the FDA's 30-day initial review period without a clinical hold.
Medicovestor, Inc. Wins First Place at the Next Star North America Biomedical Special Competition in Boston, part of the 2025 Entrepreneur Next Star Million Prize Global ChallengeBOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for cancer treatment, announced today that it has been awarded First Place in the 2025 Next Star North America Biomedical Special Competition held in Boston. This prestigious recognition highlights Medicovestor’s groundbreaking work on its two first-in-class ADC platforms, ADoBind, targeting pancreatic cancer, and ADoTope, targeting ovarian cancer.
FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic CancerNovel chemoimmunotherapy platform aims to transform outcomes in one of the world’s deadliest cancers
Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug ConjugatesNEW YORK and SHANGHAI, June 09, 2025 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) today announced a strategic partnership with Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D.
Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTONEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a leading innovator in biotechnology, today announced the issuance of two new patents and the approval of an additional patent by the U.S. Patent and Trademark Office (USPTO), further bolstering its proprietary dimeric antibody-drug conjugate (ADC) platform and a high affinity human antibody directed at a novel ADC target. The ADC platform is agnostic to antigen, antibody, indication, and payload.
Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation SummitNEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc. has been chosen as one of 11 finalists from a competitive pool of over 150 applicants spanning more than 20 countries to showcase its innovative Antibody-Drug Conjugate (ADC) platforms at the inaugural JP Morgan Asset Management: Life Sciences Innovation Summit. The event is scheduled to take place at the renowned Cleveland Clinic in Abu Dhabi on May 14th – 15th, 2024.
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platformsNEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Medicovestor, Inc, a privately-held biopharmaceutical company focused on the development of novel antibody drug-conjugate (ADC) therapies, proudly announces the successful completion of its oversubscribed Seed financing round. This momentous achievement propels the company forward in advancing pioneering research, expanding its patent portfolio, and enhancing the capabilities of Medicovestor's two state-of-the-art ADC platforms.
